Goncharov O. Role of processes of immune-inflammatory activation in the vessels remodeling in the patients with essential hypertension.

The dissertation is devoted to the study of immune-inflammatory activation, feature of arterial vessels' remodeling, endothelial function in the patients with arterial hypertension II stage, to the study of significance of inflammatory processes in development of structural and functional reorganisation of arteries, and influences of candesartan therapy on processes which were studied. In work it is proved, what arterial hypertension II stage is observed remodeling of arterial vessels, authentically increases of the thickness of an intimo-medial segment and decreases of diameter of the common carotid arteries in comparison with almost healthy people. The above mentioned disturbance progress according to degree and duration of an arterial hypertension and increases of patients' ages. The elevation level of the soluble form of an intercellular molecule of adhesion-1 in the serum is shown in the patients with arterial hypertension II stage; it is accompanied by authentic reduction endothelium-dependent and endothelium-independent vasodilatations. The strongest interrelation of systolic and pulse pressure is marked with intensity of processes vascular remodeling observes in the patient with arterial hypertension II stage. The activation of immune-inflammatory processes which progresses at increase in level of arterial pressure, age and duration of disease is proved in the patients with arterial hypertension II stage. Hyperactivity of inflammatory processes is the important factor of development of endothelial dysfunction and arterial vessels remodeling in the hypertensive patients. Use of candesartan promotes achievement of target level of arterial pressure in the majority patients with arterial hypertension II stage, leads to considerable improvement of endothelial function and to authentic decrease in levels C-reactive protein, an tumor necrosis factor-alpha and the soluble form of an intercellular molecule of adhesion-1 throughout 12 weeks of treatment.